Buy Dr Pepper On BodyArmor Investment?
Charles Sizemore | Aug 18, 2015 02:37PM ET
I love Dr Pepper Snapple’s (NYSE:DPS) original Dr Pepper. I really do. It’s a Texas thing and it’s in my blood.
I’ve been known to drive 100 miles from Dallas to Waco to get “real” Dr Pepper made with cane sugar and after I’ve been overseas for any length of time, my first stop after leaving the airport isn’t my home. It’s Whataburger. I leave my suitcase (and sometimes my wife and children) in the car and gorge myself on a disgustingly greasy Whataburger with cheese, washed down with a large Dr Pepper over crushed ice. Then I go home.
Long live Texas.
Alas, I don’t drink as much Dr Pepper as I used to. I’m too old and it goes right to my ever-expanding gut. I might have a couple sugary soft drinks per month, if that. And I’m not alone. American consumption of soft drinks has been falling for ten straight years.
Yet interestingly, while Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) have really struggled with falling unit sales of their core soft drinks, Dr Pepper Snapple has managed modest volume growth. Last quarter, DPS grew soft drink sales (which include Dr. Pepper, 7-Up and Schweppes, among a few other smaller brands) by a full 1%. And Dr Pepper has been slowly clawing market share away from Coke and Pepsi.
As a result of this trend bucking, spunky underdog DPS stock has absolutely crushed its larger rivals.
DPS is up about 80% over the past year while KO is up about 20% and PEP has barely budged at all.
Losing Bet?
But being the fastest grower in a shrinking industry is still a losing proposition, which is why the market is abuzz with the news that DPS just made an investment in up-and-coming sports drink BodyArmor, a rival of PepsiCo’s Gatorade and Coca-Cola’s Powerade. Dr Pepper Snapple’s $20 million investment gives it about a 12% interest in the company. On a side note, Los Angeles Lakers star Kobe Bryant is also a major investor in BodyArmor.
BodyArmor is still a tiny niche player in a market that is totally dominated by Gatorade. Recent data shows Gatorade with a 77% share of the sports-drink market, which in total does about $6.8 billion in annual sales. BodyArmor did a rather paltry $30 million in sales last year, giving it less than one half of one percent of the market.
Get The News You Want
So while BodyArmor is a growing brand with a lot of potential, it’s not realistically going to be a major driver of revenues for Dr Pepper Snapple, which does $6.2 billion in annual sales. Or at least not any time soon.
So, where does that leave Dr Pepper Snapple, and might DPS stock still be a decent buy?
Fundamentals
Actually, yes. DPS stock is not “cheap” -- in a strict sense -- trading at about 19 times next year’s expected earnings. But it is modestly cheaper than Coke and Pepsi and DPS is also a company with very healthy margins and a fat return on equity of over 30%.
DPS stock also sports a respectable dividend yield of 2.4% and it’s been growing that dividend at a nice clip. DPS’s quarterly dividend has more than tripled since 2010 and the company is also aggressively repurchasing its stock.
You’re probably not going to double your money in Dr Pepper Snapple any time soon. But in an overpriced market, I would expect DPS stock to deliver at least respectable total returns over the next year.
Disclosures: None
Charles Lewis Sizemore, CFA, is chief investment officer of the investment firm Sizemore Capital Management and the author of the Sizemore Insights blog.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.